Topical NF-kappa [beta] decoy in the treatment of atopic dermatitis

Journal of Drugs in Dermatology, Jan, 2006

This study is currently recruiting patients. Sponsored by Corgentech. The purpose of this study is to determine whether this topical NF-kappa [beta] decoy candidate is safe in persons with atopic dermatitis. Preliminary evidence of efficacy (whether it is working) will also be evaluated.

Condition   Intervention                 Phase

Atopic      Drug: NF-kappa [beta] Decoy  Phase II
Dermatitis                               Phase II

Study ID Numbers: 110-01P

ClinicalTrials.gov Identifier: NCT00125333